UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2010-05, Vol.21 (suppl-5), p.v126-v128

2010

Volltextzugriff (PDF)

Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

Annals of oncology, 2007-07, Vol.18 (7), p.1196-1202

2007

Volltextzugriff (PDF)

Searching for targets for the systemic therapy of mesothelioma

Annals of oncology, 2015-08, Vol.26 (8), p.1649-1660

2015

Volltextzugriff (PDF)

1IN CLINICAL TRIALS AND TRANSLATIONAL RESEARCH IN EUROPE – THE ROLE OF ETOP

Lung cancer (Amsterdam, Netherlands), 2011, Vol.71, p.S1-S1

Stahel, R.A

2011

Volltextzugriff (PDF)

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)

Lung cancer (Amsterdam, Netherlands), 2014-08, Vol.85 (2), p.306-313

2014

Volltextzugriff (PDF)

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)

Annals of oncology, 2014-01, Vol.25 (1), p.9-15

2014

Volltextzugriff (PDF)

Primary non-small cell lung cancer response upon treatment with denosumab

Lung cancer (Amsterdam, Netherlands), 2013-12, Vol.82 (3), p.506-508

2013

Volltextzugriff (PDF)

1IN MILESTONES IN THE MANAGEMENT OF LUNG CANCER

Lung cancer (Amsterdam, Netherlands), 2009, Vol.64, p.S2-S2

Stahel, R.A

2009

Volltextzugriff (PDF)

37IN EUROPEAN TREATMENT GUIDELINES: MESOTHELIOMA

Lung cancer (Amsterdam, Netherlands), 2009, Vol.64, p.S20-S20

Stahel, R.A

2009

Volltextzugriff (PDF)

Origin and prognostic value of circulating KRAS mutations in lung cancer patients

Cancer letters, 2007-09, Vol.254 (2), p.265-273

2007

Volltextzugriff (PDF)

3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial

European journal of cancer (1990), 2015-09, Vol.51, p.S711-S712

2015

Volltextzugriff (PDF)

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Annals of oncology, 2020-12, Vol.31 (12), p.1734-1745

2020

Volltextzugriff (PDF)

Lung Cancer: The European Thoracic Oncology Platform

Annals of oncology, 2012-09, Vol.23, p.ix58

Stahel, R.A.

2012

Volltextzugriff (PDF)

Personalized Therapy in Lung Cancer: The Promise for the Future

Annals of oncology, 2012-09, Vol.23, p.ix66

Stahel, R.A.

2012

Volltextzugriff (PDF)

10IN NEW TOOLS IN THE MOLECULAR DIAGNOSTIC OF LUNG CANCER

Lung cancer (Amsterdam, Netherlands), 2011, Vol.71, p.S7-S7

2011

Volltextzugriff (PDF)

Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study

Annals of oncology, 2004-03, Vol.15 (3), p.511-516

2004

Volltextzugriff (PDF)

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial

Lung cancer (Amsterdam, Netherlands), 2019-07, Vol.133, p.83-87

2019

Volltextzugriff (PDF)

25PD CIRCULATING MICRO-RNA PROFILING IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON SMALL-CELL LUNG CANCER RECEIVING BEVACIZUMAB/ERLOTINIB FIRST-LINE TREATMENT FOLLOWED BY PLATINUM-BASED CHEMOTHERAPY AT DISEASE PROGRESSION (SAKK 19/05)

Lung cancer (Amsterdam, Netherlands), 2013-05, Vol.80, p.S11-S11

2013

Volltextzugriff (PDF)

VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data

Annals of oncology, 2021-05, Vol.32 (5), p.687-688

2021

Volltextzugriff (PDF)

ETOP activity in the field of biomarkers and predictors

Lung cancer (Amsterdam, Netherlands), 2012-06, Vol.77, p.S16-S17

2012

Volltextzugriff (PDF)

Evaluating medical oncology outcomes: An Asian lung cancer study

Annals of oncology, 2019-11, Vol.30, p.ix132

2019

Volltextzugriff (PDF)

Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation

Annals of oncology, 2024-07, Vol.35 (7), p.607-629

2024

Volltextzugriff (PDF)

5IN ESMO NON-SMALL-CELL LUNG CANCER (NSCLC) CONSENSUS ON PATHOLOGY AND MOLECULAR TESTING

Lung cancer (Amsterdam, Netherlands), 2011, Vol.71, p.S4-S4

2011

Volltextzugriff (PDF)

4IN ESMO RECOMMENDATION 2011: ADVANCED NSCLC

Lung cancer (Amsterdam, Netherlands), 2011, Vol.71, p.S3-S3

2011

Volltextzugriff (PDF)

16MO Clinical impact of plasma EGFR analysis: Results from the ETOP-BOOSTER randomized phase II trial

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S49-S50

2023

Volltextzugriff (PDF)

1 – 25 von 120

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(118)
Mit Volltextzugriff
(119)

Publikationsform

Artikel
(119)
Reviews
(1)

Sprache

Englisch
(120)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(45)
Science & Technology
(45)
Oncology
(42)
Humans
(41)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
Biological And Medical Sciences
(18)
Medical Sciences
(17)
Male
(16)
Neoplasm Staging
(16)
Adult
(15)
Hematology, Oncology And Palliative Medicine
(15)
Female
(13)
Middle Aged
(13)
Pulmonary/respiratory
(12)
Pharmacology. Drug Treatments
(11)
Aged
(10)
Antineoplastic Agents
(10)
Chemotherapy
(9)
Diagnosis, Differential
(9)
Incidence
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

Searching for targets for the systemic therapy of mesothelioma

1IN CLINICAL TRIALS AND TRANSLATIONAL RESEARCH IN EUROPE – THE ROLE OF ETOP

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)

Primary non-small cell lung cancer response upon treatment with denosumab

1IN MILESTONES IN THE MANAGEMENT OF LUNG CANCER

37IN EUROPEAN TREATMENT GUIDELINES: MESOTHELIOMA

Origin and prognostic value of circulating KRAS mutations in lung cancer patients

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Lung Cancer: The European Thoracic Oncology Platform

Personalized Therapy in Lung Cancer: The Promise for the Future

10IN NEW TOOLS IN THE MOLECULAR DIAGNOSTIC OF LUNG CANCER

Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial

25PD CIRCULATING MICRO-RNA PROFILING IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON SMALL-CELL LUNG CANCER RECEIVING BEVACIZUMAB/ERLOTINIB FIRST-LINE TREATMENT FOLLOWED BY PLATINUM-BASED CHEMOTHERAPY AT DISEASE PROGRESSION (SAKK 19/05)

VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data

ETOP activity in the field of biomarkers and predictors

Evaluating medical oncology outcomes: An Asian lung cancer study

Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation

5IN ESMO NON-SMALL-CELL LUNG CANCER (NSCLC) CONSENSUS ON PATHOLOGY AND MOLECULAR TESTING

4IN ESMO RECOMMENDATION 2011: ADVANCED NSCLC

16MO Clinical impact of plasma EGFR analysis: Results from the ETOP-BOOSTER randomized phase II trial

Suchergebnisse filtern